| 22-01-07 | Delisting of AS "Olainfarm” shares from the Baltic Main list | AQ |
| 22-01-06 | Notification about results of final buy-back of shares | AQ |
| 21-12-30 | Notification about final share buy-back | AQ |
| 21-12-28 | Correction: Regarding results of a share buy-back offer | AQ |
| 21-12-28 | On substantial participation (4) - specified | AQ |
| 1 day | +7.19% |
| Manager | Title | Age | Since |
|---|---|---|---|
Juris Hmelnickis
CEO | Chief Executive Officer | 46 | 2025-12-31 |
Janis Leimanis
DFI | Director of Finance/CFO | 56 | - |
| Chief Tech/Sci/R&D Officer | - | 2009-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 2021-06-18 | |
Janis Buks
CHM | Chairman | - | 2022-08-31 |
Roberts Tavjevs
BRD | Director/Board Member | - | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/4/21 | Sell | Chief Financial Officer | 97,424 | 0.6917% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.19% | +2.67% | - | - | 148M | |
| -1.13% | -3.11% | +13.82% | +60.17% | 46.21B | |
| -0.53% | -3.88% | +33.04% | +106.96% | 38.78B | |
| +0.12% | -0.08% | +7.12% | +73.98% | 11.68B | |
| -0.53% | -1.37% | -13.25% | +11.19% | 11.55B | |
| -0.38% | -2.26% | +18.18% | +142.99% | 9.14B | |
| +0.32% | -2.26% | +23.08% | +35.61% | 7.3B | |
| +0.17% | -0.74% | +13.44% | +180.68% | 7.15B | |
| +0.41% | -3.68% | +33.65% | -19.49% | 7.1B | |
| -3.13% | -4.30% | -44.88% | +12.88% | 4.97B | |
| Average | +0.25% | -2.59% | +9.36% | +67.22% | 15.99B | |
| Weighted average by Cap. | -0.62% | -3.27% | +15.96% | +74.41% |
Employees
2,191
Sector
Pharmaceuticals
